Pharmaceutics, Volume 18, Issue 1
2026 January - 142 articles
Cover Story: This study explores therapeutic potential of bile acid derivative T3K in ulcerative colitis (UC). Using DSS-induced colitis mice, pseudo-germ-free models, and fecal microbiota transplantation, the author demonstrates that T3K alleviates colitis by enhancing intestinal barrier integrity, upregulating Mucin2 and tight junction proteins, and restoring gut microbiota homeostasis. T3K specifically enriches beneficial bacteria such as Akkermansia muciniphila, increases levels of BAs like muricholic acid (MCA), lithocholic acid (LCA), and its derivatives isoLCA, improves bile acid metabolism, and then repairs damaged intestinal mucosa. Its efficacy depends on gut microbiota, confirming that T3K acts through the microbiota–bile acid axis. These findings highlight T3K as a promising candidate for UC treatment. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.